Dexcom (DXCM) FY2014 results: revenue $259 million, up 62.0% on the year
Dexcom Inc. (DXCM) reported revenue of $259 million for fiscal 2014, the year ended 31 December 2014, up 62.0% on the year before. Net income was -$22 million, and diluted earnings per share $-0.30. The figures are the company's own, from the 10-K it filed with the SEC on 25 February 2015.
Revenue
$259 million
+62.0% on the year
FY2009FY2014
Operating margin
-8.3%
-18.1% a year earlier
FY2009FY2014
Net income
-$22 million
FY2009FY2014
Diluted EPS
-$0.30
FY2009FY2014
this yearthe year beforeHover a bar for its figure.
The year in brief
Income statement (profit and loss)
$ million
FY2014
FY2013
FY2012
On the year
Last 8 years
Revenue
259
160
99.9
+62.0%
Cost of revenue
82.9
59.9
53.3
+38.4%
Gross profit
176
100
46.6
+76.1%
Gross margin
68.0%
62.6%
46.6%
Research and development
69.4
44.8
38.3
+54.9%
Selling, general and administrative
128
84.2
64.0
+52.5%
Operating income
-21.5
-28.9
-55.7
Operating margin
-8.3%
-18.1%
-55.8%
Interest expense
0.8
0.9
0.2
-11.1%
Pre-tax income
-22.3
-29.8
-55.8
Income tax
0.1
0.0
-1.3
Net income
-22.4
-29.8
-54.5
Net margin
-8.6%
-18.6%
-54.6%
Diluted EPS
-$0.30
-$0.42
-$0.79
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2014
FY2013
FY2012
On the year
Last 8 years
Operating cash flow
23.6
2.4
-33.1
+883.3%
Capital expenditure
16.2
7.9
9.5
+105.1%
Free cash flow
7.4
-5.5
-42.6
Free cash flow margin
2.9%
-3.4%
-42.6%
Cash from investing
-16.8
20.9
28.4
Cash from financing
21.8
11.8
10.2
+84.7%
Depreciation and amortisation
8.4
7.0
6.6
+20.0%
Share-based compensation
50.0
24.6
18.4
+103.3%
Shares outstanding at period end
77m
72m
70m
+6.6%
Balance sheet
$ million
FY2014
FY2013
FY2012
On the year
Last 8 years
Shareholders' equity
140
84.1
77.0
+66.7%
Debt
4.6
6.8
7.0
-32.4%
Other liabilities
39.8
31.6
22.0
+25.9%
Total liabilities and equity
185
122
106
+50.7%
Fixed assets
31.2
20.7
18.9
+50.7%
Goodwill
3.2
3.2
3.2
0.0%
Intangible assets
2.7
3.6
4.2
-25.0%
Investments
11.8
11.4
40.6
+3.5%
Cash and equivalents
71.8
43.2
8.1
+66.2%
Receivables
42.4
n/a
n/a
Inventory
16.0
9.0
7.4
+77.8%
Other assets
5.5
31.4
23.6
-82.5%
Total assets
185
122
106
+50.7%
10-K for the year ended 31 December 2014, filed 25 February 2015: the filing.